Akero Therapeutics Statistics
Total Valuation
AKRO has a market cap or net worth of $1.55 billion. The enterprise value is $679.49 million.
| Market Cap | 1.55B |
| Enterprise Value | 679.49M |
Important Dates
The next estimated earnings date is Friday, August 9, 2024, before market open.
| Earnings Date | Aug 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AKRO has 69.15 million shares outstanding. The number of shares has increased by 26.34% in one year.
| Shares Outstanding | 69.15M |
| Shares Change (YoY) | +26.34% |
| Shares Change (QoQ) | +6.38% |
| Owned by Insiders (%) | 5.40% |
| Owned by Institutions (%) | 108.78% |
| Float | 54.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.83 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 30.12, with a Debt / Equity ratio of 0.04.
| Current Ratio | 30.12 |
| Quick Ratio | n/a |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -48.35 |
Financial Efficiency
Return on equity (ROE) is -27.80% and return on invested capital (ROIC) is -23.14%.
| Return on Equity (ROE) | -27.80% |
| Return on Assets (ROA) | -25.70% |
| Return on Capital (ROIC) | -23.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.20M |
| Employee Count | 56 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.73% in the last 52 weeks. The beta is -0.31, so AKRO's price volatility has been lower than the market average.
| Beta (5Y) | -0.31 |
| 52-Week Price Change | -49.73% |
| 50-Day Moving Average | 21.14 |
| 200-Day Moving Average | 23.18 |
| Relative Strength Index (RSI) | 50.35 |
| Average Volume (20 Days) | 1,047,943 |
Short Selling Information
The latest short interest is 7.30 million, so 10.56% of the outstanding shares have been sold short.
| Short Interest | 7.30M |
| Short Previous Month | 7.46M |
| Short % of Shares Out | 10.56% |
| Short % of Float | 13.34% |
| Short Ratio (days to cover) | 9.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -204.07M |
| Pretax Income | -179.27M |
| Net Income | -179.27M |
| EBITDA | -175.38M |
| EBIT | -175.64M |
| Earnings Per Share (EPS) | -$3.23 |
Balance Sheet
The company has $903.67 million in cash and $35.55 million in debt, giving a net cash position of $868.11 million or $12.55 per share.
| Cash & Cash Equivalents | 903.67M |
| Total Debt | 35.55M |
| Net Cash | 868.11M |
| Net Cash Per Share | $12.55 |
| Equity (Book Value) | 846.25M |
| Book Value Per Share | 12.24 |
| Working Capital | 881.02M |
Cash Flow
| Operating Cash Flow | -155.88M |
| Capital Expenditures | n/a |
| Free Cash Flow | -155.88M |
| FCF Per Share | -$2.63 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AKRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.34% |
| Shareholder Yield | -26.34% |
| Earnings Yield | -11.58% |
| FCF Yield | -10.07% |
Analyst Forecast
The average price target for AKRO is $41.43, which is 85.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $41.43 |
| Price Target Difference | 85.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |